ProCE Banner Activity

Antibody–Drug Conjugates and the Role of TROP-2 in NSCLC


Download this slideset from a live symposium at ELCC 2024 for an expert overview of TROP-2 ADCs in advanced NSCLC, including the need for new therapies in relapsed disease, what ADCs are and how they work, and TROP-2 as a therapeutic target for these new agents.

Released: March 19, 2024



David Planchard

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Paris-Saclay University
International Center for Thoracic Cancers
Villejuif, France

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.